Inactive Instrument

News Jupiter Neurosciences, Inc.

Equities

Jupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL in Parkinson's Disease	27/23/27	CI
Jupiter Neurosciences, Inc. Announces Appointment of New Chief Financial Officer	13/23/13	AQ
Jupiter Neurosciences, Inc. Appoints Saleem Elmasri as Chief Financial Officer	12/23/12	CI
Jupiter Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/22/03	CI
Jupiter Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	17/22/17	CI
Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting Use of JOTROL™	14/22/14	CI
Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	19/22/19	CI
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	26/22/26	CI
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	26/22/26	CI
Jupiter Neurosciences, Inc. Announces Broadening of IP Estate for its Unique Resveratrol Formulation, JOTROL	01/22/01	CI
Jupiter Neurosciences, Inc. Announces Completion of Phase I Safety Trial with Enhanced Resveratrol Product, JOTROL™	23/22/23	CI
Jupiter Neurosciences to Issue 2.2 Million Units in IPO	27/22/27	MT
Jupiter Neurosciences, Inc. has filed an IPO.	12/21/12	CI
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt	12/21/12	CI
Jupiter Neurosciences, Inc. Announces New Corporate Offices	21/21/21	CI

No results for this search